The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Ryzodeg



Novo Nordisk A/SEU/1/12/806/1,4,5,7,8

Main Information

Trade NameRyzodeg
Active SubstancesInsulin degludec (ideg)
Insulin aspart (iasp)
Dosage FormSolution for injection
Licence HolderNovo Nordisk A/S
Licence NumberEU/1/12/806/1,4,5,7,8

Group Information

ATC CodeA10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
A10AD06 insulin degludec and insulin aspart

Status

License statusAuthorised
Licence Issued
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back